Physicians' Academy for Cardiovascular Education

ESC 2018

PACE-CME.org was present at the ESC 2018 in Munich, Germany. Find coverage of the latest CV news on PACE-CME.

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK

Screening for high blood pressure globally

10' education - Nov. 20, 2018 - Dr. Thomas Beaney - London, Uk

Shared decision-making with lifetime risk model

10' education - Nov. 5, 2018 - Dr. Jannick Dorresteijn - Utrecht, The Netherlands

The predictive role of biomarkers in CV risk assessment

10' education - Oct. 23, 2018 - Nina Paynter, PhD - Boston, MA, USA

Women are not a subgroup: the importance of sex-specific analyses

10' education - Oct. 23, 2018 - Dr. Jeanine Roeters van Lennep, Rotterdam, the Netherlands

U-prevent predicts lifetime risk of CV events in healthy individuals

10' education - Aug. 26, 2018 - Munich, Germany - Nicole Jaspers, MD – Utrecht, The Netherlands

Population screening for atrial fibrillation with a smartphone

10' education - Aug. 26, 2018 - Munich, Germany - Prof. dr. Pieter Vandervoort - Genk, Belgium

What is the situation one year after the presentation about the CANTOS trial?

10' education - Aug. 26, 2018 - Munich, Germany - Prof. Paul Ridker, MD - Boston, MA, USA

Impressive results with transthyretin-stabilizer that reduces mortality and hospitalization in patients with transthyretin-related cardiomyopathy

3' education - Aug. 27, 2018 - Prof. Claudio Rapezzi, Bologna, Italy

Surprising result: Association very high levels of HDL-c and increased risk of CV events

3' education - Aug. 30, 2018 - Dr. Marc P Allard-Ratick, Atlanta, GA, VS

Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients

3' education - Aug. 28, 2018 - Prof. Thomas Engstrom, Copenhagen, Denmark

Can sex-specific thresholds for hs-troponin improve diagnosis of myocardial infarction?

3' education - Aug. 28, 2018 - Prof. Nicholas Mills, Edinburgh, UK

Higher healthy diet score is associated with a lower risk of mortality and CV events across the globe

3' education - Aug. 28, 2018 - Dr. Andrew Mente, Hamilton, ONT, Canada

Direct Factor Xa inhibitor does not mitigate worsening of heart failure in HFrEF patients

3' education - Aug. 27, 2018 - Prof. Faiez Zannad, Vandoeuvre Les Nancy, France

In a primary prevention setting of diabetes patients, aspirin did not give overall benefit

3' education - Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK

P2Y12 inhibitor monotherapy for 23 months after 1 month of DAPT, compared to traditional 12-month DAPT

3' education - Aug. 27, 2018 - Prof. Patrick Serruys, Rotterdam, The Netherlands

Weight loss agent showed CV safety in high-risk patients with overweight or obesity

3' education - Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US

No CV benefit with omega-3 fatty acid supplements

3' education - Aug. 26, 2018

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK
Dr. Ajay Gupta investigated the long term effects of treatment with a calcium channel blocker-based regimen and a statin on mortality in patients with hypertension, and showed a legacy effect of the combined therapy.

ESC 2018 Dr. Ajay Gupta investigated the long term effects of treatment with a calcium channel blocker-based regimen and a statin on mortality in patients with hypertension, and showed a legacy effect of the combined therapy.

Screening for high blood pressure globally

10' education - Nov. 20, 2018 - Dr. Thomas Beaney - London, Uk
Across the world, one out of five people has hypertension. In this video dr. Thomas Beaney shares the first results of the May Measurement Month project, which aims to raise awareness of high blood pressure globally in prevention of CVD.

ESC 2018 Across the world, one out of five people has hypertension. In this video dr. Thomas Beaney shares the first results of the May Measurement Month project, which aims to raise awareness of high blood pressure globally in prevention of CVD.

Shared decision-making with lifetime risk model

10' education - Nov. 5, 2018 - Dr. Jannick Dorresteijn - Utrecht, The Netherlands
Dr. Dorresteijn presents how the lifetime risk model U-prevent can estimate the effect of preventive treatment and explains the value of this model in shared decision-making.

ESC 2018 Dr. Dorresteijn presents how the lifetime risk model U-prevent can estimate the effect of preventive treatment and explains the value of this model in shared decision-making.

The predictive role of biomarkers in CV risk assessment

10' education - Oct. 23, 2018 - Nina Paynter, PhD - Boston, MA, USA
Biomarkers play an important role in CV risk prediction. Nina Paynter, PhD, presents the definition of a good biomarker and explains how deep learning can improve CV risk assessment.

ESC 2018 Biomarkers play an important role in CV risk prediction. Nina Paynter, PhD, presents the definition of a good biomarker and explains how deep learning can improve CV risk assessment.

Women are not a subgroup: the importance of sex-specific analyses

10' education - Oct. 23, 2018 - Dr. Jeanine Roeters van Lennep, Rotterdam, the Netherlands
Women are still underrepresented in CV clinical trials. Dr. Jeanine Roeters van Lennep explains why sex-specific analyses are important in research into efficacy and safety of CV medication.

ESC 2018 Women are still underrepresented in CV clinical trials. Dr. Jeanine Roeters van Lennep explains why sex-specific analyses are important in research into efficacy and safety of CV medication.

U-prevent predicts lifetime risk of CV events in healthy individuals

CSI Munich

10' education - Aug. 26, 2018 - Munich, Germany - Nicole Jaspers, MD – Utrecht, The Netherlands
Nicole Jaspers, MD, presents a model that predicts lifetime risk of CV events in individuals without CVD, including lifetime benefit of therapy, which allows shared-decision making in daily practice.

ESC 2018 Nicole Jaspers, MD, presents a model that predicts lifetime risk of CV events in individuals without CVD, including lifetime benefit of therapy, which allows shared-decision making in daily practice.

Population screening for atrial fibrillation with a smartphone

CSI Munich

10' education - Aug. 26, 2018 - Munich, Germany - Prof. dr. Pieter Vandervoort - Genk, Belgium
Prof. dr. Pieter Vandervoort, Jean-Paul Vendeville and Gijs Berkelmans discuss how digital health can help us screening for atrial fibrillation in general population by using a smartphone.

ESC 2018 Prof. dr. Pieter Vandervoort, Jean-Paul Vendeville and Gijs Berkelmans discuss how digital health can help us screening for atrial fibrillation in general population by using a smartphone.

What is the situation one year after the presentation about the CANTOS trial?

CSI Munich

10' education - Aug. 26, 2018 - Munich, Germany - Prof. Paul Ridker, MD - Boston, MA, USA
Cilie van 't Klooster asks Prof. Ridker how the results on canakinumab from the CANTOS trial can be implemented in clinical practice and which challenges are left?

ESC 2018 Cilie van 't Klooster asks Prof. Ridker how the results on canakinumab from the CANTOS trial can be implemented in clinical practice and which challenges are left?

ESC debate | First-line therapies in HFrEF - ACE inhibitors or sacubitril/valsartan?

ESC 2018 - debates

ESC 2018 The benefit of sacubitril/valsartan in HFrEF is not subject to debate, but opinions do vary on when to use it. An impression of the arguments on whether or not it should be the starting treatment.

Impressive results with transthyretin-stabilizer that reduces mortality and hospitalization in patients with transthyretin-related cardiomyopathy

3' education - Aug. 27, 2018 - Prof. Claudio Rapezzi, Bologna, Italy
In a randomized trial treatment with tafamidis resulted in impressive, significantly reduced mortality and hospitalization due to CV events in patients with ATTR-CM and HF.

ESC 2018 In a randomized trial treatment with tafamidis resulted in impressive, significant reduced mortality and hospitality due to CV events in patients with ATTR-CM and HF.

Surprising result: Association very high levels of HDL-c and increased risk of CV events

3' education - Aug. 30, 2018 - Dr. Marc P Allard-Ratick, Atlanta, GA, VS
Dr Allard-Ratick shares the surprising result that HDL-C levels >60 mg/dl (1.5 mmol/L) were associated with a nearly two-fold increase in the risk of CV death or MI in adults with CV disease.

ESC 2018 Dr Allard-Ratick shares the surprising result that HDL-C levels >60 mg/dl (1.5 mmol/L) were associated with a nearly two-fold increase in the risk of CV death or MI in adults with CV disease.

THE GREAT DEBATE: Thrombocardiology post-COMPASS

ESC 2018 - Debates
ESC 2018 - Debates

ESC 2018 In one of this year’s organized debates, it was discussed how the COMPASS trial results should or should not change clinical practice; an impression of the arguments of both sides.

ESC 2018
ESC 2018